【摘要】 目的对改良FOLFOX6新辅助化疗与术后化疗治疗进展期胃癌的临床疗效进行对比分析。方法选取200例进展期胃癌患者,并将其随机分为2组,改良FOLFOX6新辅助化疗组和改良FOLFOX6术后辅助化疗组,以进行单纯手术的100例为对照组,对比观察术后的临床疗效以及围术期并发症情况。结果改良FOLFOX6新辅助化疗组治疗后患者的总有效率(87.00%)明显高于改良FOLFOX6术后辅助化疗组患者的总有效率(57.00%),统计学上有意义(P<0.05)。同时,改良FOLFOX6新辅助化疗组患者的手术后围术期并发症发生率(22.00%)明显低于单纯手术治疗组并发症发生率(49.00%),差异在统计学上有意义(P<0.05)。结论改良FOLFOX6新辅助化疗对进展期胃癌的临床治疗效果较改良FOLFOX6术后辅助化疗的治疗效果显著,围术期并发症较少,安全可靠,可以在临床上广泛应用。更多还原

【Abstract】 Objective To compare the clinical efficacy of improved FOLFOX6 neoadjuvant chemotherapy and postoperative chemotherapy for advanced gastric carcinoma. Methods 200 patients with advanced gastric carcinoma were randomly divided into improved FOLFOX6 neoadjuvant chemotherapy group and postoperative chemotherapy group,each with 100 cases. 100 patients who received surgery was the control group,clinical efficacy and perioperative complications of patients were compared and observed. Results Total effective rate of improved FOLFOX6 neoadjuvant chemotherapy group after treatment( 87. 00%) was significantly higher than that of postoperative chemotherapy group( 57. 00%),there had statistical difference( P < 0. 05). And complication rate of improved FOLFOX6 neoadjuvant chemotherapy group( 22. 00%) was significantly lower than that of postoperative chemotherapy group( 49. 00%),there had statistical difference( P < 0. 05). Conclusion Improved FOLFOX6 neoadjuvant chemotherapy for advanced gastric carcinoma is more effective than postoperative chemotherapy with less perioperative complications. It is safe and reliable,and can be widely promoted in clinic.更多还原